[Market Focus] Pharmaresearch Jumps 6% on Expectations of Record-High Results for 12 Consecutive Quarters

On the morning of October 20, Pharmaresearch showed strong performance in early trading. This is due to expectations that the company will achieve record-high results for 12 consecutive quarters.

As of 9:38 a.m. on this day, Pharmaresearch was trading at 589,000 won, up 37,000 won (6.70%) from the previous trading day.

This is interpreted as investor sentiment concentrating on the stock, driven by expectations of solid third-quarter results.

On this day, Kim Chunghyun, a researcher at Mirae Asset Securities, stated, "Third-quarter revenue is expected to reach 142.2 billion won, a 59% increase year-on-year, thanks to robust growth in the core medical device business. This meets market expectations, and it appears the company will achieve record-high results for 12 consecutive quarters."

Researcher Kim added, "In 2025, we expect revenue to reach 570.3 billion won, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) to reach 253.9 billion won, and operating profit to reach 237.1 billion won, supported by continued solid growth."

This content was produced with the assistance of AI translation services.